Michael Kalos
- Oncology top 0.05%
- CAR-T cell therapy research 58
- Cancer Immunotherapy and Biomarkers 10
- Immunology top 0.2%
- Immunotherapy and Immune Responses 20
- Immune Cell Function and Interaction 15
- T-cell and B-cell Immunology 10
- Genetics top 0.2%
- Virus-based gene therapy research 15
- Chronic Lymphocytic Leukemia Research 10
- Virology top 1%
- Hematology top 1%
-
- Acute Lymphoblastic Leukemia research 9
- Co-authors
- Carl H. JuneBruce L. LevineDavid L. PorterAdam BaggStephan A. GruppAnne ChewSharyn I. KatzDavid M. Barrett
- Cited by
- OncologyImmunologyGenetics
- Partner nations
- United StatesNetherlandsSwitzerland
In The Last Decade
Michael Kalos
97 papers receiving 15.2k citations
Hit Papers
Peers
Comparison fields: 5 of 142
- Oncology 11.7k
- Immunology 6.0k
- Genetics 4.1k
- Virology 585
- Hematology 972
Countries citing papers authored by Michael Kalos
This map shows the geographic impact of Michael Kalos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Kalos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Kalos more than expected).
Fields of papers citing papers by Michael Kalos
This network shows the impact of papers produced by Michael Kalos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Kalos. The network helps show where Michael Kalos may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Michael Kalos, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 7 | |
| 2 | 2016 | 141 | |
| 3 | 2016 | 5 | |
| 4 | 2015 | 233 | |
| 5 | 2014 | 363 | |
| 6 | Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIVbreakdown → | 2014 | 973 |
| 7 | 2013 | 181 | |
| 8 | Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignanciesbreakdown → | 2013 | 693 |
| 9 | Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapybreakdown → | 2013 | 459 |
| 10 | 2013 | 18 | |
| 11 | Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemiabreakdown → | 2013 | 2631 |
| 12 | 2012 | 131 | |
| 13 | 2011 | 182 | |
| 14 | 2010 | 38 | |
| 15 | 2010 | 25 | |
| 16 | 2009 | 47 | |
| 17 | 2004 | 38 | |
| 18 | 2004 | 61 | |
| 19 | 2002 | 32 | |
| 20 | 2001 | 57 |
About Michael Kalos
Michael Kalos is a scholar working on Oncology, Immunology, Genetics, Genetics and Biotechnology, having authored 97 papers that have together received 15.5k indexed citations. Recurring topics across this work include CAR-T cell therapy research (58 papers), Immunotherapy and Immune Responses (20 papers), Virus-based gene therapy research (15 papers), Immune Cell Function and Interaction (15 papers), Chronic Lymphocytic Leukemia Research (10 papers), Cancer Immunotherapy and Biomarkers (10 papers), T-cell and B-cell Immunology (10 papers) and Acute Lymphoblastic Leukemia research (9 papers). The work is most often cited by research in Oncology (11.7k citations), Immunology (6.0k citations), Genetics (4.1k citations), Virology (585 citations) and Hematology (972 citations). Michael Kalos has collaborated with scholars based in United States, Netherlands and Switzerland. Frequent co-authors include Carl H. June, Bruce L. Levine, David L. Porter, Adam Bagg, Stephan A. Grupp, Anne Chew, Sharyn I. Katz, David M. Barrett, David T. Teachey and Richard Aplenc. Their work appears in journals such as Blood, Cancer Research, Cancer Immunology Research, Cancer Immunology Immunotherapy and Journal of Translational Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.